Shutterstock
An Israeli AI tool is helping those undergoing IVF in three London clinics. The tool, named Chloe, an acronym for ‘Cultivating Human Life through Optimal Embryos’, acts to determine whether an embryo can lead to a viable pregnancy.
Developed by Fairtility in Tel Aviv, the tool monitors an embryo continuously from fertilisation to days five and six to determine the likelihood of a successful pregnancy. Chief Medical Officer and co-Founder of Fairtility, Professor Assaf Ben Meir, who is also Director of the Fertility and IVF Unit at Hadassah Hospital, explained that “Chloe detects biomarkers that humans are unable to detect, identifies these features and analyses them to determine embryo quality.” Chloe “provides consistent and unbiased insights previously unavailable that embryologists and physicians can use to make more informed decisions and offer transparency to prospective parents on their embryos.”
Suzanne Cawood, Director of Embryology at the Centre for Reproductive and Genetic Health said that “Fairtility’s AI makes IVF more efficient and accessible to the growing population of people seeking fertility treatment.”
Chloe is being utilised by IVF London, the Harley Street Fertility Clinic, and the Centre for Reproductive and Genetic Health. It is also aiding clinics in Spain, Turkey, Greece and Norway.
Between 1991 and 2021, the Human Fertilisation and Embryology Authority (HFEA) recorded around 1.3 million IVF cycles in the UK, with 53,000 patients and 69,000 cycles of IVF in 2019 alone. According to data published by the World Health Organisation (WHO) in April this year, “approximately one in every six people of reproductive age worldwide experience infertility in their lifetime.”
